Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 3/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL146163 | 0.98 | ITGB3 (0.41) | ITGB3ITGA2BHRH3FAAHGBA1 | |
| Bromide SCHEMBL11261498 | 0.98 | ITGB3 (0.41) | ITGB3ITGA2BHRH3FAAHGBA1 | |
| SCHEMBL2544949 | 0.93 | ITGB3 (0.41) | ITGB3ITGA2BHRH3FAAHGBA1 | |
| SCHEMBL1838111 | 0.91 | ITGB3 (0.40) | ITGB3ITGA2BHRH3FAAHGBA1 | |
| SCHEMBL11261846 | 0.91 | ITGB3 (0.40) | ITGB3ITGA2BHRH3FAAHGBA1 | |
| Hydrochloric Acid SCHEMBL1844095 | 0.91 | ITGB3 (0.40) | ITGB3ITGA2BHRH3FAAHGBA1 | |
| Hydrochloric Acid SCHEMBL7419436 | 0.89 | GNAO1 (0.42) | ITGB3ITGA2BHRH3FAAHGBA1 | |
| Hydrochloric Acid SCHEMBL31752969 | 0.89 | GNAO1 (0.42) | ITGB3ITGA2BHRH3FAAHGBA1 | |
| Acetic Acid SCHEMBL7445844 | 0.88 | ITGB3 (0.46) | ITGB3ITGA2BFAAHGNAO1TPSAB1 | |
| SCHEMBL1431005 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 756 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2769721-A2 | Process for the preparation of substituted pyrimidine derivatives | Janssen Pharmaceutica N.V. (BE) | 2014-08-27 | — | — | EP | claimed |
| EP-1827434-B1 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| JP-2011526910-A | — | — | 2011-10-20 | — | — | JP | claimed |
| CN-102137672-A | Process for the preparation of substituted pyrimidine derivatives | JANSSEN PHARMACEUTICA NV | 2011-07-27 | — | — | CN | claimed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | claimed |
| EP-2310012-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2011-04-20 | — | — | EP | claimed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | claimed |
| WO-2010002774-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | WO | claimed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | claimed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | claimed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | claimed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | ITGB3 1246/4885ITGA2B 1908/4885HRH3 340/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | ITGB3 1269/4885ITGA2B 1738/4885HRH3 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.